Aptima Combo 2® assay (for CT/NG)

STIs are on the rise. Chlamydia (CT) and gonorrhea (NG) can have serious long-term consequences including pelvic inflammatory disease (PID), ectopic pregnancy and infertility.1 Accurate testing and treatment are critical to protecting sexual and reproductive health. The Aptima Combo 2® assay delivers reliable results from multiple specimen types, including self and clinician-collected vaginal swabs with the Aptima® Multitest Swab — the preferred specimen type of the CDC for CT and NG testing.

Aptima HPV +ThinPrep Cervical Health

Leading the charge in cervical disease prevention with the ThinPrep® system and Aptima® HPV assays

Hologic has remained an unwavering advocate for women’s health for more than two decades. Our goals as a company are intrinsically tied to changes in best-practices for women’s health, applying the latest findings in diagnostic medicine to the development of new products and technologies in response to the emergence of new discoveries in medicine.

Aptima Multitest Swab Specimen Collection Kit

Women’s health testing streamlined with just one swab. With innovative nucleic acid amplification test (NAAT) technology and a single collection device, the Aptima Multitest Swab simplifies testing and provides more answers for sexual and vaginal health.

Aptima® CMV Quant Assay

FDA-Approved solution to reliably and efficiently deliver actionable viral load insights to post-transplant patients and their care teams.  

Aptima® HBV Quant Assay

Deliver trusted results with dual targets across a wide linear range and all major HBV genotypes.

Aptima® HCV Quant Dx Assay

Confirmation of active HCV infection and monitoring HCV viral load on the fully automated Panther® system.  

Aptima® Herpes Simplex 1 & 2 assay

Globally, over 4.1 billion people are infected with HSV-1 and HSV-2 and the signs and symptoms can overlap.1 It is only through laboratory tests that these subtypes can be differentiated, which is important for managing herpes infections and identifying the risk of transmission to neonates and among sex partners.2,3

Aptima® HIV-1 Quant Dx Assay

Dual-claim assay to confirm HIV-1 infection and measure viral load.

Aptima® STIs

STI testing for improved sexual health. The Aptima STI portfolio supports sexual health testing with a comprehensive, flexible menu of sexually transmitted infection (STI) assays.


Aptima® Trichomonas vaginalis assay

Trichomonas vaginalis (TV) is the most common curable STI in the United states.1 Over 3.7 million people in the United States have TV, which is a higher prevalence than chlamydia and gonorrhea infections combined.1 The CDC recommends testing women for TV infection if they are symptomatic or at increased risk of infection.2 The CDC and ACOG also recommend the use of a highly sensitive and specific test, such as the Aptima® Trichomonas vaginalis assay.2,3

Aptima® Vaginal Health

The Aptima vaginitis panel from Hologic consists of molecular nucleic acid amplification tests (NAAT) to aid in the detection of vaginosis and vaginitis. Our assays detect the three most common causes of infectious vaginitis: bacterial vaginosis, candida vaginitis and trichomoniasis.

Aptima® Virology

The Aptima Virology portfolio delivers on the Hologic promise of innovation through life-changing viral testing for viruses that impact patients across the globe.

Direct Load Capture Cap Collection Kit

Transform specimen processing with the only nasopharyngeal (NP) swab that loads directly for COVID testing.

No specimen transferExpedite your SARS-CoV-2* workflow with a collection device that loads directly on the Panther® system.  The Direct Load Capture Cap Collection Kit is authorized for use with the Aptima® SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays.

Direct Load Tube Collection Kit

Transform Specimen Processing for COVID Testing

No uncapping and no specimen transfer. Expedite your SARS-CoV-2* workflow with a collection device that loads directly on the Panther® system. The Direct Load Tube Collection Kit is authorized for use with the Aptima® SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays.

Hologic SARS-CoV-2 Assays

The emergence of SARS-CoV-2 was unforeseen, and the worldwide outbreak of COVID-19 has already impacted millions Since then, the need and recommendations for testing for SARS-CoV-2 have continuously evolved, requiring labs to be flexible with their strategies over time. Hologic’s SARS-CoV-2 portfolio and scalable automation enable labs to react to these changing needs and fully automate COVID-19 testing. With Panther® Scalable Solutions, you can run over 1000 tests in 24 hours, attaining first results in about 3 hours.1† The Panther Fusion® SARS-CoV-2 assay is a real-time PCR test and the Aptima® SARS-CoV-2 assay utilizes our proprietary TMA® technology. Both assays are intended for the qualitative detection of RNA from SARS-CoV-2 isolated and purified from nasopharyngeal, nasal, mid-turbinate and oropharyngeal swab specimens, nasopharyngeal wash/aspirate or nasal wash, and lower respiratory tract specimens (Panther Fusion assay only) obtained from individuals who meet COVID-19 clinical and/or epidemiological criteria.2,3 These assays are also intended for upper respiratory tract swab samples from individuals without symptoms or other reasons to suspect COVID-19 infection. The Aptima SARS-CoV-2/Flu assay utilizes our proprietary real-time TMA chemistry to detect and differentiate SARS-CoV-2, influenza A and influenza B from nasopharyngeal and nasal swabs obtained from individuals with signs and symptoms of a respiratory tract infection or who meet COVID-19 clinical and/or epidemiological criteria.4

Hologic Transplant Assay

Give patients a better chance at life with our Transplant Portfolio of quantitative tests for the quantification of post-transplant infections.  

CMV and Viral Load Monitoring

Cytomegalovirus (CMV) infection is a common complication that affects organ transplant patients. CMV, a member of the herpes virus family, establishes a lifelong latent infection that is generally asymptomatic. However, in immunocompromised patients, such as transplant recipients, reactivation of latent CMV is often life-threatening. Guidelines recommend regular monitoring of CMV viral load as an aid for diagnosis of CMV infections and monitoring response to treatment.1, 2